Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates
07:34pm, Monday, 27'th Feb 2023
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the s
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
04:05pm, Tuesday, 21'st Feb 2023
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today
Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice
01:33pm, Thursday, 02'nd Feb 2023
Does Revolution Medicines, Inc. (RVMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Revolution Medicines to Participate in Upcoming Investor Conferences
07:00am, Thursday, 02'nd Feb 2023
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou
Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?
04:31am, Thursday, 12'th Jan 2023
Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further st
Where Revolution Medicines Stands With Analysts
06:04pm, Wednesday, 14'th Dec 2022 Benzinga
Analysts have provided the following ratings for Revolution Medicines (NASDAQ:RVMD) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
03:01pm, Wednesday, 14'th Dec 2022 Benzinga
Upgrades
Wolfe Research upgraded the previous rating for EQT Corp (NYSE:EQT) from Peer Perform to Outperform. EQT earned $1.04 in the third quarter, compared to $0.12 in the year-ago quarter. At the m
Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
04:04pm, Thursday, 08'th Dec 2022 Benzinga
U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session.
Design Therapeutics, Inc. (NASDAQ: DSGN) shares dip
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
09:05pm, Wednesday, 07'th Dec 2022 GlobeNewswire Inc.
Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combination with sotorasib is expected to be unaffected Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combinatio
Revolution Medicines: Highly Differentiated Offering Gaining Traction
04:35pm, Wednesday, 07'th Dec 2022
Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitors that's standing up well in safety, efficacy. The company is well-capitalized to continue operat
Revolution Medicines to Participate in Upcoming Investor Conferences
09:05pm, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ann
Revolution Medicines to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 09'th Nov 2022
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou
Revolution Medicines, Inc. (RVMD) Q3 2022 Earnings Call Transcript
10:58pm, Monday, 07'th Nov 2022
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Ex
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates
10:55pm, Monday, 07'th Nov 2022 Zacks Investment Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates
07:35pm, Monday, 07'th Nov 2022
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
